ACC 2022 This randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.

ACC 2022 In the DIAMOND trial, use of patiromer not only resulted in maintenance of lower levels of potassium (K+) compared to placebo, but also in a lower risk of hyperkalemia events and in enablement of RAASi therapy in HFrEF patients on RAASi therapy.

ACC 2022 Although a reduction in sodium intake in HF patients did not result in a reduction of all-cause mortality of CV hospitalization compared to usual care, patient-centered outcomes were improved.

ACC 2022 What are the findings of the DIAMOND trial with the potassium binder patiromer in patients with HFrEF who were on RAASi therapy?

ACC 2022 Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

ACC 2022 The SODIUM-HF trial showed that a dietary intervention to reduce sodium intake did not reduce clinical events in ambulatory patients with HF. However, sodium reduction improved quality of live and NYHA class.

ACC 2022 An analysis showed that treatment with empagliflozin in patients with acute HF resulted in clinical benefit, regardless of symptomatic impairment at baseline, and improved symptoms, physical function and quality of life.

ACC 2022 Based on results from the SODIUM-HF trial, what can you tell your patients with heart failure when they take a small amount of salt and worry about harmful effects?

Empagliflozin has received approval from the European Commission for the treatment of symptomatic chronic HF across the full spectrum of LVEF.

Iron deficiency is very common in HF patients, also in patients who are nonanemic. Therefore, you need to measure it and treat it, conclude Robert Mentz and Peter van der Meer.

Patients with HFpEF and normal natriuretic peptide levels display abnormalities in cardiac structure, -function, and hemodynamic parameters, as well as a higher risk for mortality or HF hospitalization compared with controls with dyspnea due to non-cardiac causes.

Three experts talk about findings from clinical trials with the non-steroidal MRA finerenone in patients with CKD and T2DM and how to implement these findings in daily clinical practice.